加科思-B(01167.HK) 公布，在加利福尼亚州圣地亚哥举行的2024年第66届美国血液学会(ASH)年会上，展示了BET抑制剂“JAB-8263”治疗骨髓纤维化(MF)临床一期的初步数据。
资料指，“JAB-8263”具有良好的耐受性，二期推荐剂量为0.3毫克(每日给药)。“JAB-8263”单药治疗骨髓纤维化适应症的初步疗效资料是令人鼓舞的。大多数患者出现脾脏缩小及总症状评分的降低。
加科思透露，截至今年10月17日的数据，已有16名中/高风险骨髓纤维化患者被纳入研究，其中13名患者接受至少一次治疗后疗效评估。(js/w)
(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.